(NASDAQ:FOSL), Third quarter 2025 worldwide net sales totaled $270 million Third quarter operating loss of $22 million and operating margin of (8)%; constant currency adjusted operating loss of $15 million and constant currency adjusted operating margin of (6)% Completes balance sheet transformation, significantly strengthens financial position subsequent to quarter end Reiterates full year 2025 financial […]
(NASDAQ:VOR), Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune Diseases Expansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected gross proceeds of $115 million raised in the November 2025 underwritten public offering, including the underwriters' full exercise of the option to purchase additional shares BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) —
(NASDAQ:AMAT), Record annual revenue $28.37 billion, up 4 percent year over year Record annual GAAP EPS $8.66 and record non-GAAP EPS $9.42, up 1 percent and 9 percent year over year, respectively Quarterly revenue $6.80 billion, down 3 percent year over year Quarterly GAAP EPS $2.38 and non-GAAP EPS $2.17, up 14 percent and down
(NASDAQ:RLMD), Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key elements of Phase 3 program with two independent paths for approval in two separate NMIBC indications: High-risk 2nd line BCG-unresponsive, and Intermediate-risk patients in
(TSX:FRU), CALGARY, Alberta, Nov. 13, 2025 (GLOBE NEWSWIRE) — Freehold Royalties Ltd. (Freehold or the Company) (TSX:FRU) announces third quarter results for the period ended September 30, 2025. Third Quarter Highlights $74 million in revenue; $59 million in funds from operations ($0.36/share) (1)(2); $44 million in dividends paid ($0.27/share)(3); 16,054 boe/d(4) of total production, a
(NasdaqGM:TELA), MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $20.7 million, a 9% increase from the third quarter of
(NASDAQ:ELTX), In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), fewer disease progressions and deaths than projected have been observed as of November 6, 2025. Based on 2:1 randomization with twice as many patients in the ELI-002 7P treatment arm compared to the observation arm, Elicio believes
(NASDAQ:BNGO), SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2025. “Over the last year, we have taken decisive steps to transform our business model by focusing on driving consumables and software utilization among our existing routine use customers. We
(TSX:FRX),(NASDAQ:FENC), ~ Q3 2025 Total Net Product Sales of $12.5 Million, 79% Year Over Year Growth ~ ~ Q3 2025 Positive Cash Flow from Operations, Cash Position Grew to $22 Million ~ ~ Japan Clinical Trial (STS-J01) Preliminary Results Expected in Q4 2025 ~ RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) — Fennec
(NASDAQ:AMRX), BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company's iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare's Omnipaque(R) (iohexol) injection. Amneal expects to launch the product in the first